Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

NCT07004335 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

PD-(L)1
CTLA-4
Advanced Melanoma
Iparomlimab
Tuvonralimab
Bevacizumab

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection plus Bevacizumab

Sponsor

Hebei Medical University Fourth Hospital

Collaborators

[object Object]